Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative
Sivera, F.; Andres, M.; Carmona, L.et al.
2014 • In Annals of the Rheumatic Diseases, 73 (2), p. 328-35
[en] We aimed to develop evidence-based multinational recommendations for the diagnosis and management of gout. Using a formal voting process, a panel of 78 international rheumatologists developed 10 key clinical questions pertinent to the diagnosis and management of gout. Each question was investigated with a systematic literature review. Medline, Embase, Cochrane CENTRAL and abstracts from 2010-2011 European League Against Rheumatism and American College of Rheumatology meetings were searched in each review. Relevant studies were independently reviewed by two individuals for data extraction and synthesis and risk of bias assessment. Using this evidence, rheumatologists from 14 countries (Europe, South America and Australasia) developed national recommendations. After rounds of discussion and voting, multinational recommendations were formulated. Each recommendation was graded according to the level of evidence. Agreement and potential impact on clinical practice were assessed. Combining evidence and clinical expertise, 10 recommendations were produced. One recommendation referred to the diagnosis of gout, two referred to cardiovascular and renal comorbidities, six focused on different aspects of the management of gout (including drug treatment and monitoring), and the last recommendation referred to the management of asymptomatic hyperuricaemia. The level of agreement with the recommendations ranged from 8.1 to 9.2 (mean 8.7) on a 1-10 scale, with 10 representing full agreement. Ten recommendations on the diagnosis and management of gout were established. They are evidence-based and supported by a large panel of rheumatologists from 14 countries, enhancing their utility in clinical practice.
Disciplines :
Rheumatology
Author, co-author :
Sivera, F.
Andres, M.
Carmona, L.
Kydd, A. S.
Moi, J.
Seth, R.
Sriranganathan, M.
VAN DURME, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative
Smith EU, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010;24:811-27.
Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis 2008;67:1310-16.
Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007;19:122-7. (Pubitemid 46208769)
Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15. (Pubitemid 47492473)
Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol 2011;17:349-55.
Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11. (Pubitemid 44641591)
Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.
Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61.
Hamburger M, Baraf HS, Adamson TC III, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123:3-36.
Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48(Suppl 2):ii9-14.
Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv. 1-72.
Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2011;70:15-24.
Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) 2012;51:1416-25.
Higgins J, Altman Re. Chapter 8: Assessing the risk of bias in included studies. In: Higgins J, Green S. eds. Cochrane handbook for systematic reviews of interventions Version 501 (updated September 2008). The Cochrane Collaboration, 2008. http://www.cochrane-handbook.org
Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37. (Pubitemid 46768164)
Newcastle-Ottawa quality assessment scale: case control studies. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm (accessed 4 Feb. 2012).
Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 2010;19:539-49.
Reitsma J, Rutjes A, Whiting P, et al. Chapter 9: Assessing methodological quality. In: Deeks J, Bossuyt P, Gatsonis C, eds. Cochrane handbook for systematic reviews of diagnostic test accuracy (Version 1.0.0). The Cochrane Collaboration, 2009. http://srdta.cochrane.org
Schumacher HR, Taylor W, Edwards L, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
Oxford Center for Evidence-Based Medicine: levels of evidence (March 2009). http://www.cebm.net/index.aspx?o=1025 (accessed 4 Feb. 2012).
Glazebrook KN, Guimaraes LS, Murthy NS, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology 2011;261:516-24.
Janssens H, Fransen J, van de Lisdonk E, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010;170:1120-6.
Lai K, Chiu Y. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound 2011;19:7-13.
Malik A, Schumacher HR, Dinnella JE, et al. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009;15:22-4.
Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricaemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50. (Pubitemid 39237608)
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Int Med 2009;169:342-50.
Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kdney disease among middle-aged and elderly men and women with gout in the Singapour Chinese health study. Ann Rheum Dis 2012;71:924-8.
Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010;123:957-61.
Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypert 2001;19:1209-15. (Pubitemid 32595276)
Goldberg RJ, Burchfiel CM, Benfante R, et al. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. Arch Intern Med 1995;155:686-94.
Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. (Pubitemid 29310011)
Puddu PE, Lanti M, Menotti A, et al. Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study. Acta Cardiol 2001;56:243-51. (Pubitemid 32848607)
Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136-43. (Pubitemid 30171270)
Chien KL, Hsu HC, Sung FC, et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 2005;183:147-55.
Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006;37:1503-7. (Pubitemid 44305733)
Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 2006;187:401-7. (Pubitemid 43963022)
De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010;69:1162-4.
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900. (Pubitemid 47300913)
Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141-6.
Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42. (Pubitemid 18069583)
Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10. (Pubitemid 351749228)
van Durme CMPG, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout (Protocol). Cochrane Database Syst Rev 2012;10:CD010120.
Wechalekar MD, Vinik O, Schlesinger N, et al. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; (4): CD009920.
Sivera F, Wechalekar MD, Andrés M, et al. Interleukin-1 inhibitors for acute gout (Protocol). Cochrane Database Syst Rev 2012;7:CD009993.
Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4. (Pubitemid 18014682)
Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
Garcia de la Torre I. A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis. Invest Med Int 1987;14:92-7.
Lederman R. A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344-54.
Weiner GI, White SR, Weitzner RI, et al. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
Valdes EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987;9:133-6. (Pubitemid 18059081)
Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. J Med Assoc Thai 1985;68:111-16. (Pubitemid 15003099)
Sturge RA, Scott JT, Hamilton EB, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis 1977;36:80-2. (Pubitemid 8038411)
Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973;32:351-3.
Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6.
Schumacher HR Jr., Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92. (Pubitemid 34666615)
Maccagno A, DiGiorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134-9. (Pubitemid 16044387)
Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittelforschung 1983;33:641-3. (Pubitemid 13127047)
Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970;10:275-80.
Cheng TT, Lai HM, Chiu CK, et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406.
Butler RC, Goddard DH, Higgens CS, et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985;20:511-13. (Pubitemid 16193361)
Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum 2004;50:598-606. (Pubitemid 38202232)
Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007;46:1126-32. (Pubitemid 47050616)
Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60. (Pubitemid 351736009)
Man CY, Cheung ITF, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7. (Pubitemid 46601694)
Moi JHY, Sriranganathan MK, Edwards CJ, et al. Lifestyle interventions for chronic gout (Protocol). Cochrane Database Syst Rev 2013;5:CD010039.
Andres M, Sivera F, Falzon L, et al. Dietary supplements for chronic gout (Protocol). Cochrane Database Syst Rev 2012;11:CD010156.
Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis 2012;71:929-34.
Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23. (Pubitemid 40372228)
Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711-20.
Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
Reinders MK, Haggsma C, Jansen TL, et al. A randomized-controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
NICE. Febuxostat for the management of hyperuricemia in people with gout (Structured abstract). London: National Institute for Health and Clinical Excellence (NICE), 2008.
Stevenson M, Pandor A. Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 2011;29:133-40.
Ferraz M, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurent gouty arthritis. J Rheumatol 1995;22:908-14.
Borstad CG, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gout arthritis. J Rheumatol 2004;31:2429-32. (Pubitemid 39610535)
Paulus HE, Schlosstein SH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
Vazquez-Mellado J, Meooo Morales E, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3. (Pubitemid 32885676)
Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56. (Pubitemid 14216359)
Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled. J Clin Rheumatol 1999;5:49-55. (Pubitemid 29217861)
Hosoya T, Ichida K, Tabe A, et al. Combined therapy using allopurinol and benzbromarone for gout and hyperuricemia complicated with renal disorder. Jpn J Rheumatol 1992;4:77-90.
Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British health professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
Meyers OL, Cassim B, Mody GM. Hyperuricaemia and gout: clinical guideline 2003. S Afr Med J 2003;93:961-71.
Romeijnders AC, Gorter KJ. Dutch College of General Practitioners' Gout standards. Ned Tijdschr Geneeskd 2002;146:309-13. (Pubitemid 34150285)
Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006;55:786-90. (Pubitemid 44619193)
Sarawate AC, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5. (Pubitemid 44309598)
Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009;15:3-7.
Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and attacks of gouty arthritis: evidence of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5. (Pubitemid 38725128)
Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minize risk of gouty attacks during anty-hyperuricemic therapy. Adv Exp Med Biol 1998;431:13-18. (Pubitemid 28236731)
Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009;36:1032-40.
Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
McCarthy G, Barthelemy CR, Veum JA, et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991;34:1489-94.
Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010;30:495-503.
Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80. (Pubitemid 32202663)
Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8. (Pubitemid 47122319)
Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
Khanna PP, Perez-Ruiz F, Maranian P, et al. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology 2011;50:740-5.
Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. Validation of the health assessment questionnaire disability index in patients with gout. Arthritis Care Res 2008;59:665-9. (Pubitemid 351679541)
Dalbeth N, Clark B, Gregory K, et al. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum 2007;57:457-61.
Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93. (Pubitemid 350067651)
Sriranganathan MK, Vinik O, Bombardier C, et al. Interventions for tophi in gout. Cochrane Database Syst Rev 2012;9:CD010069.
Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-33. (Pubitemid 350193621)
Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011;6:1887-94.
Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9. (Pubitemid 41828266)
Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Qual Saf Health Care 2009;18:385-92.
3e Methodology. http://www.3erheumatology.com/en/3emethodology.aspx (accessed 27 Apr. 2013).
